PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial

The Phase III Belinda study investigating Kymriah (tisagenlecleucel) for treatment of non-Hodgkin lymphoma did not meet its primary endpoint of event-free survival c...
Continue Reading →
News

New data at ESC Congress 2021 showcase AstraZeneca’s leading cardiovascular, renal and metabolic portfolio

At this year's European Society of Cardiology (ESC) Congress (27-30 August), AstraZeneca is sharing ...
Continue Reading →
News

FDA approves first COVID-19 vaccine

The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be market...
Continue Reading →
News

FDA approval for Xywav for idiopathic hypersomnia in adults

Jazz Pharmaceutical’s Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults has been granted...
Continue Reading →
News

Moderna’s COVID-19 vaccine maintains antibodies to six months, study shows

New data published on the durability of the Moderna COVID-19 vaccine in generating neutralising antibodies against variants of concern has shown that the majority of...
Continue Reading →
News

FDA approves Keytruda plus Lenvima for advanced kidney cancer

The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the fi...
Continue Reading →
News

Further clinical trial planned for Valneva’s COVID-19 vaccine candidate

Valneva is planning to initiate a further Phase III trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The new VLA2001-304 s...
Continue Reading →
News

US rejects AZ and FibroGen’s anaemia drug roxadustat

The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat. AZ had submitted a new dru...
Continue Reading →
News

Takeda takes the lead on Finch’s ulcerative colitis candidate FIN-524

Takeda has elected to accelerate the transition of development responsibility for Finch Therapeutics' FIN-524, an investigational oral microbiome therapy in developm...
Continue Reading →
News

AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the European Commission for the treatment of chronic ...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026